Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes and sometimes obesity. GLP-1 RAs are very effective at lowering blood sugar levels.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation involving this class of drugs. Over the past few years ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Back to Healio NATIONAL HARBOR, Md. — GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about the long-term effects of these ...

The researchers found that while most glucose-lowering therapies were not significantly associated with a reduction in dementia risk, one class of drugs—known as GLP-1 receptor agonists (GLP ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Increased awareness and knowledge of GLP-1/GIP receptor agonists among women, with insights into public perspectives on ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4% in 2022. As a result, annual spending jumped from $1.6 billion to $5. ...